PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
CONCLUSION: Buparlisib plus weekly paclitaxel might be a new treatment option for patients with metastatic MCB harboring a PIK3CA mutation. Additional prospective studies for investigating the efficacy of the proposed combination are warranted.
PMID: 30577988 [PubMed - as supplied by publisher]
Source: J Formos Med Assoc - Category: General Medicine Authors: Yang MH, Chen IC, Lu YS Tags: J Formos Med Assoc Source Type: research
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Epithelial Cancer | General Medicine | Science | Stem Cell Therapy | Stem Cells | Study | Toxicology